Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 87

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 87
---
 | Yes. The Semnur stockholders are required to approve the Business Combination. |

Scilex entered into the Company Stockholder Support Agreement with Denali and Semnur, pursuant to which Scilex agreed to vote all Semnur Common Stock beneficially owned by it, including any additional shares of Semnur it acquires ownership of or the power to vote, in favor of the Business Combination and related transactions. As of the date of this proxy statement/prospectus, Scilex owns all of the issued and outstanding shares of Semnur Common Stock. 32

| Q: | Are there risks associated with the Business Combination that I should consider in deciding how to vote? |

| A: | Yes. There are a number of risks related to the Business Combination and other transactions contemplated by the Merger Agreement that are discussed in this proxy statement/prospectus. Please read with particular care the detailed description of the risks described in “Risk Factors” beginning on page 72 of this proxy statement/prospectus. |

| Q: | May I seek statutory appraisal rights or dissenter rights with respect to my shares? |

| A: | No. Appraisal rights are not available to holders of Denali Ordinary Shares in connection with the Business Combination or the Domestication Proposal. For additional information, see the section titled “The Meeting — Appraisal Rights.” |

| Q: | Who will manage New Semnur after the Business Combination? |

| A: | As a condition to the closing of the Business Combination, all of the officers and directors of Denali will resign, so that effective at the Closing, the New Semnur Board will consist of five individuals, a majority of whom will be independent directors in accordance with the requirements of Nasdaq. For information on the anticipated management of New Semnur, see the section titled “Directors and Executive Officers of New Semnur After the Business Combination” in this proxy statement/prospectus. |

| Q: | Who can help answer my questions about the Proposals and related matters? |

| A: | If you have questions about the Business Combination or if you need additional copies of this proxy statement/prospectus, any document incorporated by reference in this proxy statement/prospectus or the enclosed proxy card, you should contact: |

Advantage Proxy, Inc. Toll-Free: (877) 870-8565 Collect: (206) 870-8565 Email: ksmith@advantageproxy.com You also may